Do Antimicrobial Peptides and Complement Collaborate in the Intestinal Mucosa? by ZoÃ« A. Kopp et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW ARTICLE
published: 30 January 2015
doi: 10.3389/fimmu.2015.00017
Do antimicrobial peptides and complement collaborate in
the intestinal mucosa?
Zoë A. Kopp1, Umang Jain1, JohanVan Limbergen1,2 and AndrewW. Stadnyk 1,2*
1 Department of Microbiology and Immunology, Faculty of Medicine, Dalhousie University, Halifax, NS, Canada
2 Department of Pediatrics, Faculty of Medicine, Dalhousie University, Halifax, NS, Canada
Edited by:
Cordula M. Stover, University of
Leicester, UK
Reviewed by:
Koichi S. Kobayashi, Texas A&M
Health Science Center, USA
KazueTakahashi, Massachusetts
General Hospital, USA
*Correspondence:
AndrewW. Stadnyk, Mucosal
Immunology Research, IWK Health
Centre, 8W, 5850 University Avenue,
Halifax, NS B3K 6R8, Canada
e-mail: astadnyk@dal.ca
It is well understood that multiple antimicrobial peptides (AMPs) are constitutively deployed
by the epithelium to bolster the innate defenses along the entire length of the intestines.
In addition to this constitutive/homeostatic production, AMPs may be inducible and levels
changed during disease. In contrast to this level of knowledge on AMP sources and roles in
the intestines, our understanding of the complement cascade in the healthy and diseased
intestines is rudimentary. Epithelial cells make many complement proteins and there is
compelling evidence that complement becomes activated in the lumen. With the com-
mon goal of defending the host against microbes, the opportunities for cross-talk between
these two processes is great, both in terms of actions on the target microbes but also on
regulating the synthesis and secretion of the alternate family of molecules.This possibility
is beginning to become apparent with the finding that colonic epithelial cells possess ana-
phylatoxin receptors. There still remains much to be learned about the possible points of
collaboration between AMPs and complement, for example, whether there is reciprocal
control over expression in the intestinal mucosa in homeostasis and restoring the balance
following infection and inflammation.
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INTESTINAL EPITHELIUM AND INNATE DEFENSE
The cell boundary of the intestinal mucosa, interfacing the envi-
ronment through the lumen, is comprised of a single-layer colum-
nar epithelium, which in turn is composed of multiple cell types.
These cells are undergoing constant renewal from epithelial stem
cells in the crypt, with support of other epithelial and stromal
cells in the niche. Progeny from the stem cells differentiate into
the four specialized epithelial cell lineages; absorptive enterocytes
with metabolic/digestive functions, mucus-secreting goblet cells,
digestive-hormone secreting enteroendocrine cells, and Paneth
cells. Paneth cells differ from other intestinal epithelial cells (IECs)
in that they remain at the base of the crypts instead of migrating
up the crypt during differentiation. Paneth cells are the major
producer of antimicrobial peptides (AMPs) and they live longer
than other IECs, surviving at the base of the crypt for approx-
imately 20 days (1). IECs are interconnected through multiple
molecular links but paramount among these are tight junctions,
which control the permeability of the epithelial monolayer. Finally,
scattered within the epithelium is a peculiar population of lym-
phocytes, the intraepithelial lymphocytes (IEL). IEL are squeezed
between the basolateral borders of IECs and the two cell types
communicate in maintaining the epithelial barrier (2). Mouse IEL
reportedly express AMPs following exposure to bacteria (3). There
undoubtedly remains more to be learned about IEL in defining the
antimicrobial properties of the epithelium.
In addition to the cellular barrier, the innate defenses in the
intestinal tract include highly glycosylated mucins (muc), secreted
by goblet cells (4). The epithelium of the small intestine is over-
layed with a single unattached mucus layer while two defined layers
of mucus protect the colonic epithelium. In the colon, the inner
layer is physically attached to the epithelium while the outer layer is
unattached. Commensal microorganisms inhabit the outer, lower
density mucus layer of the colon. Not surprisingly, degradation
of the mucus layers permits contact between the IEC and bac-
teria. Illustrating the outcome of a comprised mucus layer, mice
lacking MUC-2 develop colitis (5). In addition to mucins, gob-
let cells also produce trefoil factors, in particular trefoil factor 3
(TFF3), which facilitates mucin crosslinking and promotes epithe-
lial repair, as well as resistin-like molecule-B (RELM-B), which
stimulates MUC-2 secretion (4). TFF3 also induces a complement
regulatory molecule, decay accelerating factor (DAF) on IEC (6).
The mucus layer(s) are further impregnated with soluble factors
that fortify the defensive capabilities. Secretory IgA, synthesized
by B lymphocytes in the lamina propria, is transported into the
mucus layer by IEC. Finally, AMPs and complement are found in
the lumen, in the mucus.
AMPs OF THE IEC
There are multiple families of AMPs suggesting an evolutionary
divergence in the intestinal mucosa, a rich habitat for microbes and
a principle route of infection of the host. AMPs are active against a
variety of organisms including gram-positive and gram-negative
bacteria, parasites, fungi, and enveloped viruses (Table 1) (7).
Although there are many AMPs, the majority share a few
common structural features including an overall positive charge
(due to lysine and arginine residues) and an increased attrac-
tion to the hydrophobicity of bacterial membranes, due to an
abundance of hydrophobic amino acid residues (7). Mentioned
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Table 1 | Properties of AMPs in the intestines.
Antimicrobial mechanism Specificity Murine version
α-defensins
HD-5 Pore-forming Gram-negative, gram-positive, viruses, fungi, parasite Cryptidins
HD-6 Nanonet Gram-negative, gram-positive, viruses, fungi, protozoa Cryptidins
β-defensins
hBD-1,2 Pore-forming Gram-negative mBD-1 (hBD-1) mBD-3 (hBD-2)
hBD-3 Pore-forming Gram-negative, gram-positive mBD-14
hBD-4 Pore-forming Gram-negative, gram-positive, fungi
C-type lectin
RegIIIα Unknown Gram-positive RegIIIγ
Cathelicidin
LL-37 Pore-forming Gram-positive, gram-negative, viruses, fungi, protozoa CRAMP
Others
Secretory phospholipase A2 Degradation of membrane
phospholipids
Gram-positive –
Lysozyme Peptidoglycan hydrolysis Gram-positive –
earlier, Paneth cells are the main though not the exclusive source
of AMPs. In response to IL-22, Toll-like receptor (TLR) and
nucleotide oligomerization domain (NOD-2) signaling Paneth
cells secrete lysozyme, secretory phospholipase A2 (sPLA2), α-
and β-defensins, the C-type lectin regenerating islet-derived pro-
teins (Reg), angiogenin 4, and cathelicidins in the small intestine,
with the α-defensins being the most abundant (1, 4, 8). Paneth
cell secretion of AMPs is important in maintaining spatial seg-
regation of the intestinal microbiota from the epithelium (9).
RegIIIγ-deficient mice consequently exhibit a defect in this seg-
regation and microbes penetrate the mucus layer making intimate
contact with host cells (10). In addition to providing AMPs, Paneth
cells also help maintain crypt stem cells through the production
of pro-growth factors such as WNT3 and Notch ligands (11).
Enterocytes are widely reported to produce AMPs including β-
defensins (hBD-1,2,3,4), RegIIIα, and LL-37/human cationic AMP
18 (4, 12, 13). In fact, in mice temporary enterocyte expression
of cathelin-related antimicrobial peptide (CRAMP) is important
in allowing neonatal small intestinal colonization prior to the
establishment of Paneth cells (14).
DEFENSINS
Defensins, arguably the most studied and well understood family
of AMPs, target the surface membrane of microbes and function by
forming pores leading to increased permeability of the membrane
and the interruption of electrochemical gradients (Table 1) (15).
The polypeptides are translated as an inactive precursor, which
is cleaved to an active form. The primary protein sequence is a
87–94 residue peptide including a hydrophobic leader sequence, a
short acidic pro-piece (which neutralizes the peptide), and a highly
cationic mature sequence (7). Subtypes of defensins undergo dif-
ferent post-translational processing into an active cationic peptide,
for example, in mice enteric α-defensins (cryptidins) are activated
by matrix metalloproteinase matrilysin (MMP-7) (16). MMP-7 is
a member of the metalloproteinase family of proteolytic enzymes
produced by stromal fibroblasts and Paneth cells that degrade the
extracellular matrix (17). Contrasting the situation in mouse cells,
human Paneth cells only contain the pre-form of HD-5 and MMP-
7 is undetectable (1). Thus, while human HD-5 was reported to
be susceptible to MMP-7 cleavage, detection of a human homolog
of the enzyme in the intestinal mucosa remains to be reported
(18). Instead, an isoform of trypsin produced by Paneth cells
was found to activate the protein resulting in multiple interme-
diates with variable levels of bactericidal activity (18, 19). Finally,
a shorter amino-terminal extension in the human β-defensins
permits bactericidal activity of the pre-forms (19). Otherwise
the active defensins are 20–40 amino acids in length with three
intramolecular disulfide bonds formed by a six-cysteine consen-
sus sequence. The position of these intramolecular bonds is used
to classify the family into α, β, and ζ defensins, with ζ defensins
restricted to Rhesus monkeys (1).
α-Defensins
Alpha-defensins are classified based on a conserved pattern of six
cysteines, which are linked 1–6, 2–4, and 3–5 (20). There are six
subtypes of human α-defensins, four of which are found exclu-
sively in neutrophils (HNP-1,2,3,4) and two of which are found in
Paneth cells (HD-5,6), called the “enteric defensins” (1). Enteric
defensins are found in rodents but the leukocyte α-defensins are
not (1).
HD-5 exhibits direct bactericidal activity through a pore-
forming mechanism but in an interesting contrast to the typi-
cal permeability-altering property of AMPs, HD-6 exhibits anti-
bacterial activity indirectly (Table 1). HD-6 reportedly forms
trap-like structures, which do not kill but instead immobilizes
bacteria. HD-6 polymerizes to form peptide nanonets, which
inhibit microbes from translocating across the intestinal barrier
(21). Another difference is that HD-5 exhibits anti-parasite activ-
ity while HD-6 does not. Otherwise both human α-defensins share
similar molecular structures, both exhibit anti-viral activity and
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FIGURE 1 | Generalized depiction of AMP expression along the axes of
the intestines. (A) Pattern of expression in the longitudinal axis, comparing
the healthy (left) with inflamed (right) intestines. The thickness of the
bar/triangle for each AMP roughly depicts the relative concentration of that
particular AMP. For example, RegIIIα is found along the small intestine with
highest levels in the ileum and low levels in the large intestine. α-Defensins
are also predominantly expressed in the small intestine with levels
corresponding with the increasing abundance of Paneth cells from the
duodenum to ileum. The longitudinal distribution of complement has not
been characterized. (B) The epithelium of the small intestine is organized
into crypts and villi, or in the case of the large intestine, crypts, and surface
epithelium (e.g., lacks villi), which create a vertical axis along which
differentiating cells migrate. Some AMPs are secreted from different cell
types along this axis. For example, β-defensins are secreted by goblet cells,
Paneth cells, and enterocytes and thus are produced in locations along the
crypt-villus axis.
both have been reported to be restricted to Paneth cells. HD-5 and
HD-6 mRNAs are most highly concentrated in the ileum where
Paneth cell abundance is highest (Figure 1A) (22). Relatively high
levels of HD-5 are also detectable in the jejunum while levels of
both HD-5 and 6 are low in the colon (21) (Figure 1).
β-Defensins
There are four human β-defensins (hBD-1,2,3,4), which are all
expressed in keratinocytes and epithelial cells in a variety of human
tissues (7, 20). The human β-defensins share a similar molecular
structure with conserved cysteine residues linked 1–5, 2–4, 3–6
(20). With the exception of hBD-2, all human β-defensins are
constitutively expressed in the small and large intestine (Figure 1).
hBD-2 is unique in that it is detectable in low amounts in healthy
tissues but is inducible with IL-1 (13). The molecules are expressed
in Paneth cells and enterocytes and are all active against gram-
negative bacteria. hBD-3 and hBD-4 additionally are active against
gram-positive bacteria and are chemotactic for monocytes. hBD-
1 mRNA is present in IEC at low levels throughout the intestines
with highest expression in the colon (22).
RegIIIα
RegIIIα (also known as human hepatocarcinoma-intestine
pancreas/pancreatitis-associated protein), is an AMP expressed in
the liver, brain, and intestines of humans (23). It is present in the
duodenum, jejunum, ileum, and colon, with expression highest
in the crypts of the small intestine (Figure 1) (24). RegIIIα is a
member of a large family of Reg genes but is one of only two
RegIII genes found in humans (23). All are members of the C-
type lectin family that bind glycan chains of peptidoglycan on the
cell wall of gram-positive bacteria (25). The murine C-type lectin,
RegIIIγ, is 65% identical to human RegIIIα and exhibits similar
peptidoglycan binding (25). Paneth cells and enterocytes but not
goblet cells express RegIIIγ (24, 25). Noteworthy, RegIIIγ lacks
the complement recruitment domains present in other microbe-
binding mammalian C-type lectins [such as mannose-binding
lectin (MBL)] suggesting it is limited to direct anti-bactericidal
activity (25).
LL-37
LL-37 is an AMP expressed in epithelial cells, keratinocytes, neu-
trophils, mast cells, monocytes, NK cells, B-cells, and γδ T cells
(20). LL-37 belongs to the cathelicidin family of AMPs and func-
tions in a similar way to defensins, by puncturing holes in the
surface membrane of microbes (Table 1). LL-37 is unique in
that in addition to antimicrobial activity, it has other immuno-
logical activities, acting through various receptors on cells (26).
These activities include chemotaxis, wound healing, angiogenesis,
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degranulation of mast cells, and neutralizing lipopolysaccharide
(LPS) and lymphotoxin-A (LTA) (26). LL-37 expression can be
either constitutive or inducible. In the intestine, LL-37 is produced
constitutively by cells above the transit-amplifying zone in colonic
crypts, with lower levels detected in the small intestine (Figure 1B)
(27). Production can be increased when these cells are stimulated
with short chain fatty acids (27).
Thus a picture emerges in which the mucus layer resting on
the healthy epithelium is rich with AMPs, although the pattern of
expression along the intestines implies specializations among the
different molecules (Figure 1) (11). The idea that AMPs show dif-
ferential distribution is also evident at another level, roughly along
the crypt-to-villus axis (Figure 1B). For example, β-defensins are
secreted by goblet cells, Paneth cells, and enterocytes and thus are
produced along the crypt-villus axis (22) while hBD-3,4 expres-
sion is highest in cells of the lower crypt (12). RegIIIα is produced
by Paneth cells in the crypts of the small intestine and detected in
the crypt and lower villi (24, 28). Similarly, α-defensins are pre-
dominantly expressed by Paneth cells in the base of the crypts
although HD-5 has been detected in villous epithelial cells of the
jejunum and ileum (13, 29).
EPITHELIAL AMP EXPRESSION DURING INFLAMMATION
The cellular composition of the intestinal mucosa changes sig-
nificantly during inflammation. This is in part due to the large
numbers of infiltrating AMP-producing leukocytes as well as dif-
ferences in the relative abundance of epithelial cell types resulting
in altered expression of constitutive AMPs. One reported dif-
ference between the healthy and chronically inflamed intestinal
epithelium impacting on AMP expression is an increased abun-
dance of metaplastic Paneth cells in the colon (1). Colonic meta-
plastic Paneth cells produce α-defensins, lysozyme, and sPLA2
(1). sPLA2, in particular, is not detected in the healthy colon
but is expressed by metaplastic Paneth cells as well as some
colonocytes during inflammation (30). Other AMPs are also
increased during inflammation. Murine RegIIIγ expression was
increased during bacterial exposure and mucosal inflammation,
and human RegIIIα expression was reported increased in patients
with IBD (25, 31). Alpha-defensins are also induced in the large
intestine during inflammation, associated again with metaplas-
tic Paneth cells (1). Considering the importance of Paneth cells
in providing AMPs, mutations in microbe sensing molecules in
Paneth cells are thought to directly impact defensin production.
However, the specific microbiome has emerged as an impor-
tant factor in influencing defensin production even in mice with
defects in these sensing molecules. This was demonstrated when
defensin secretion by Nod2 gene knockout mice reverted to wild-
type levels after exposure of the knockout mice to wild-type
microbiota in co-housing experiments (32). Mixed findings have
been reported for other AMPs and inflammation. hBD-1 lev-
els have been reported to not change between the healthy and
inflamed gut but contrarily, have also been shown to decline in
ulcerative colitis (21, 33, 34). hBD-2,3, and 4 levels reportedly
increase during ulcerative colitis but not Crohn’s disease (12). LL-
37 expression reportedly does not change during inflammation
(27, 35). Thus, the impact of inflammation on AMP expres-
sion varies based on the AMP and the specific disease, and the
generalizations in Figure 1A should not be understood to apply to
all diseases.
Studies from gene knockout mice
Much of what we know about the role of AMPs in the intestines
is derived from research done using mice. The importance of α-
defensins in gut homeostasis was shown by examining the gut
microbes of matrilysin deficient (MAT−/−) mice, recalling that
MMP-7 is required for α-defensin activation in mice (16). The
lack of active α-defensins resulted in an impaired ability to control
levels of both non-invasive and invasive bacteria in the intestines
(16). Additionally, the oral lethal dose of an invasive strain of
S. typhimurium was 90% less than that of the wild-type mice
(16). Similar findings of increased susceptibility to bacteria were
observed with mice experiencing graft versus host disease, which
includes injury to Paneth cells resulting in reduced α-defensin
production. Reduced α-defensin expression in turn was associ-
ated with changes in commensal bacteria populations and lower
numbers of the major enteric commensals and higher num-
bers of minor enteric commensals (E. coli) led to septicemia in
the mice (36).
Alpha-defensin expression in mice has been reported to be
Nod2 dependent and consequently the Nod2 gene knockout
mouse (Nod2−/−) has been a popular model to study (37).
Nod2−/− mice reportedly have higher levels of commensal bac-
teria as well as a reduced ability to prevent pathogenic enteric
bacterial colonization (38). Nod2−/− mice infected by L. monocy-
togenes had lower numbers of specific cryptidins in their terminal
ileum and were less successful in defending against the pathogen
than wild-type mice. The mice also had larger populations of bac-
teria in their livers and spleens (37). Nod2−/− mice challenged
with Helicobacter hepaticus suffered from granulomatous inflam-
mation of the ileum but Nod2−/− expressing transgenic HD-5
killed the bacteria (39). However, again, these experiments were
conducted without necessarily controlling for the impact of the
microbiota.
Transgenic expression of HD-5 was used in other infectious
models. Compared to wild-type mice, overexpression of HD-5
protected mice from infection by S. typhimurium. Wild-type strain
mice died while the transgenic mice experienced less severe disease,
less colonization, and recovered (40). These outcomes support the
idea that defensins mediate protection beyond the regulation of
commensal populations of microorganisms.
The role of cathelicidins has also been explored using mouse
models. In addition to the role of CRAMP in colonization of
the neonatal gut, CRAMP is also involved in the response to
injury. Mouse colons inflamed with DSS showed increased lev-
els of mCRAMP. mCRAMP−/− mice experienced worse colitis,
which was reversible using exogenous mCRAMP or mCRAMP-
encoding plasmids, confirming that the cathelicidins are protec-
tive in the colon (41, 42). In another study, cathelicidin deficient
mice (camp−/−) displayed a thinner inner colonic mucus layer
than wild-type mice and had lesions on the surface epithelium
due to a higher incidence of penetration and colonization by
E. coli O157 (43).
Similar to the camp−/− mice, RegIIIγ−/− mice also presented
with changes in mucus distribution and incidence of bacteria
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on the mucosa of the ileum (44). A significant reduction in the
amount of mucus was detected in RegIIIγ−/− mice due to changes
in MUC-2 expression (44). Bacteria were observed in contact with
the surface epithelium in the knockout mice; however, it is unclear
whether this was due to the absence of the bactericidal activity
of RegIIIγ or a consequence of changes in mucus distribution.
RegIIIγ−/− mice were also reported to have higher numbers of
gram-negative bacteria in their feces (44).
Taken together, the evidence that AMPs are important in the
defense of the healthy and inflamed intestines is compelling. Yet it
is not entirely clear why there is such a diversity of AMPs, some with
varying patterns of expression along the length of the intestines.
Additionally, even in the studies using gene knockout mice, it can-
not be concluded that the AMPs act alone and directly to affect
the phenotypes reported (for example, the role of the microbiome
in shaping the AMP response was illustrated in Nod2−/− mice).
There remains a high likelihood that AMPs act in concert with
other defenses to achieve homeostasis and recover following injury
and inflammation. The complement system is now emerging as
one such parallel defense mechanism.
COMPLEMENT AND THE INTESTINE
Complement comprises a set of soluble proteins and membrane
receptors and regulators that function in a highly coordinated
manner to destroy microbes and facilitate removal of apop-
totic/necrotic cells. Split complement molecules link the innate
and adaptive immune systems, indirectly by acting on antigen
presenting cells and directly by acting on leukocytes including
lymphocytes. Despite the known crucial involvement of these
functions in modulating the local response to microbes, the role
of complement in the intestines is not completely understood.
Complement activation primarily occurs through one of the
three pathways: the classical pathway (CP), lectin pathway (LP),
and/or alternative pathway (AP) – all converging at the C3 con-
vertase step. C3 convertases cleave C3 into C3a and C3b. C3b then
associates with the C3 convertase to form a C5 convertase, which
cleaves C5 into C5a and C5b. C5b become the nidus for bind-
ing C6, C7, C8, and C9 molecules to form the membrane attack
complex (MAC), the lytic machinery of complement.
Each route of activation has proximal effectors that double as
pattern recognition molecules. C1q, a proximal CP protein, com-
bines with immune complexes forms a multimolecular complex
with serine proteases, C1r and C1s. This complex cleaves C4 then
associates with the product C4b into a complex, which cleaves
C2 to form the CP C3 convertase. The LP is initiated by binding
of MBL/ficolins to the mannose residues on microbial surfaces.
Bound MBL recruits MBL-associated serine proteases (MASP-1
and MASP-2) that function similar to C1r and C1s by cleaving
C4 and C2 to form the classical C3 convertase. The AP is unique
as it does not require pattern recognition molecules to become
activated. Instead, a “tick over” mechanism involves the sponta-
neous hydrolysis of C3 into C3(H2O), which behaves similar to
C3b and binds factor B (fB). Through a series of reactions involv-
ing factor D (fD) and properdin, the C3bBb complex forms the
AP C3 convertase [reviewed in Ref. (45)]. Two additional models
of AP activation have been proposed; (1) properdin, acting as a
pattern recognition molecule, binds to a surface and provides a
platform for C3 convertase assembly and, (2) C3b attached to a
surface binds properdin, which in turn promotes AP convertase
formation (46–48). In addition to the three principal pathways,
evidence has emerged showing that complement may be acti-
vated through other mechanisms. For example, MBL can cleave
C3 through a C2 by-pass activation mechanism (49, 50). MASPs
reportedly cleave C3 to C3b thereby triggering the AP (51). Addi-
tionally, MASP-1, without the requirement of MBL, may cleave
factor D from the pro- to mature form, again leading to AP activa-
tion (52). Finally, some coagulation pathway proteases can directly
cleave C5 and C3 (53). Finally, an opinion has emerged that the AP
may not be an entirely independent pathway but rather is respon-
sible for complement amplification that was initiated by other
pathways (54, 55).
COMPLEMENT IN THE INTESTINAL LUMEN
With regard to bolstering innate defenses in the mucosa, it is
important to know whether complement proteins are present in
the lumen. This question has not been systematically or compre-
hensively studied and the current understanding is incomplete.
In support of complement in the lumen are published accounts
of split complement molecules on the mucosa. In one example,
C3b and MAC proteins were detected on the surface epithelium
in patients with Crohn’s disease and ulcerative colitis (56, 57).
In another report that measured complement in lumen samples,
higher C3 and C4 levels were found in jejunal secretions from
Crohn’s disease patients compared to healthy participants (58).
Complement proteins were also detected in lumen samples col-
lected from the small intestine of patients experiencing bacterial
overgrowth (59). Noteworthy, and at odds with complement in
the lumen, these authors failed to find MAC proteins, suggesting
the MAC is not present (active) in the lumen. When considering
where complement in the lumen may be derived from the pan-
creatic epithelium has been identified as a source of complement,
with exocrine secretions arming at least the duodenum (60). Oth-
erwise multiple reports identify epithelial cells as a source, for
example, C4 mRNA was detected in both healthy participants’ and
Crohn’s disease patients’ mucosa while C3 expression was limited
to crypt cells in inflamed samples (61). A lack of C3 detection
in epithelial cells was repeated in another study that did detect
C3 in colonic subepithelial myofibroblasts (62). Factor B proved
to be among the most highly increased complement molecules
in epithelial cells in inflamed mucosa of IBD patients compared
to healthy donor mucosa, suggesting that inflammation leads to
arming the AP in the intestine (63). On the other hand, MBL
has not been detected in mouse or human mucosa suggesting
this proximal activator of the LP may not be active (64). Despite
the lack of C3 detection using in situ techniques, C3 has com-
monly been found in epithelial cell lines. Bemet-Camard et al.
reported that T84, Caco-2, HT-29, and a non-transformed IEC
line (INT407) were all positive for C3 and C4 (65). Another study
repeated the finding that Caco-2 cells produce C4 and fB but also
C3 (66). In addition to constitutive production, stimulation of IEC
with cytokines such as TNF, IL-6, and IL-1β increased the produc-
tion of complement proteins (66). However, consistent with the
lack of MAC in the luminal secretions from small intestine, this
study failed to detect MAC mRNAs. How is the lack of local MAC
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synthesis compatible with the detection of MAC on the mucosa?
Bleeding in ulcerated parts of the intestines could result in com-
plement in the lumen. Additionally, infiltrating leukocytes make
complement and could act as a source. Neutrophils are the lead-
ing source of properdin and by providing properdin following
infiltration these cells, neutrophils may mediate AP amplifica-
tion in the lumen (46, 67). Altogether, these findings suggest that
the intestinal epithelium does not synthesize all the complement
molecules and this raises questions over what role complement
therefore plays in the healthy intestines. During inflammation,
the remaining proteins are perhaps provided by infiltrating cells
and/or blood resulting in complete pathways, and local activation
becomes possible. Finally, the idea that complement activation
occurs, including through the MAC, is indirectly supported by
epithelial cells possessing CD55 and CD59 on the apical surface.
These membrane proteins are negative regulators of the conver-
tases and MAC, respectively (68). As for complement impacting
the intestinal epithelium from the lumen, we reported that cell
lines apically express the C5aR and respond to C5a with increased
CXCL8 mRNA, introducing the possibility that anaphylatoxins
provide danger signals to the epithelium (69). In summary, many
complement proteins are present in the uninflamed mucosa and
complement is activated during inflammatory conditions, open-
ing the possibility that AMPs and complement may collaborate
to enhance the innate defenses in health and disease in the
intestines.
COMPLEMENT AND AMP CROSS-TALK AT THE INTESTINAL
MUCOSA
Secreted into the mucus layer, there is good reason to suppose these
two antimicrobial systems interact on microbial targets but also
possibly through the reciprocal regulation of expression, whether
agonistically and/or antagonistically (Figure 2). The fact is that
such interactions have not yet been described in the intestines and
we can only hypothesize on the manner of interaction. Noteworthy
is a recent report from Chehoud et al. who found that antagoniz-
ing C5aR resulted in a decline in diversity of the skin microbiota of
healthy mice associated with changes in immune effectors includ-
ing AMPs (70). Such a relationship between split complement
effectors, AMPs, and microbes could certainly be active in the
intestines.
FIGURE 2 | Models speculating on reciprocal interactions between
AMPs and complement expression in the intestines. The first model is
inferred from the example of C5aR blocked mice showing deficiencies in
skin AMPs. The others remain to be tested.
AMP/COMPLEMENT COLLABORATION?
One obvious functional convergence between AMPs and comple-
ment is the common antimicrobial activity. Complement activa-
tion leads to antimicrobial activity with the MAC but surprisingly,
C3a also has microbicidal activity. The antimicrobial specificity of
C3a and other peptides following cleavage of C3 is broad, includ-
ing gram-negative and gram-positive bacteria (71) and fungi (72).
C3 has a long history of evolution and was present before elements
of the MAC evolved. Perhaps primitive organisms depended on C3
split products having direct antimicrobial activities. Perhaps also
related to this long evolutionary history is the discovery that cells,
including epithelial cells, constitutively make and cleave C3 into
C3a as an autocrine survival signal (73). It will be interesting to
know whether there is a relationship between C3a antimicrobial
potency and organisms which depend more on innate defenses,
compared to higher vertebrates with adaptive immune defenses.
In addition to acting independently to repel microbes, these
two systems may collaborate by reducing the effective concen-
tration needed for lysis when both are present. Experiments to
test this potential have not yet been reported but are certainly
achievable. In another manner, HD-6 presents an interesting pos-
sibility for collaboration with complement,drawing on an example
from neutrophils. Mentioned earlier, HD-6 forms a lattice in the
mucus; how closely this lattice resembles neutrophil extracellular
traps (NETs) is not clear but NETs do collaborate with comple-
ment. NETs are the discharged nuclear and cytoplasm contents of
dying neutrophils giving their best final effort to impede microbes.
C1q binds to NETs leading to complement activation (74). The
HD-6 lattice could function as a foundation for focusing comple-
ment activation by complement pattern recognition molecules like
properdin. By this mechanism the contribution of HD-6 may be
ensuring complement activation occurs, in addition to the physical
impedance of microbes.
Contradicting the speculation that the two systems may act in
synergy is a report showing that an AMP can interrupt comple-
ment activation, at least in vitro. Bhat and co-workers found that
HBD-2 (but not HBD-1) bound C1q and prevented activation of
the classical pathway in vitro (75).
RECIPROCAL CONTROL OVER EXPRESSION
Another likely point of interaction between complement and
AMPs is the possibility that there is reciprocal control over expres-
sion of the two systems (Figure 2). An example can be drawn
from more primitive organisms, mosquitoes, where C3-like mol-
ecules drive AMP expression in order to control viruses (76). In
this regard, it would be interesting to know whether mice deficient
in specific AMPs, as discussed earlier, respond by increasing local
complement concentrations or possibly respond with reduced lev-
els if the AMP directly impact complement synthesis. On the other
hand, and considering that some AMPs are constitutively pro-
duced and that complement is present but not activated (with
perhaps cytoplasmic C3 being the exception), the reciprocal situ-
ation may be true: that activated complement products impact
AMP expression. Anaphylatoxin receptor gene knockout mice
have been applied in various models of colitis with an incom-
plete understanding of whether other innate defenses have been
compromised. A rational line of investigation will be to determine
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the impact of anaphylatoxins on AMP expression in IEC, including
Paneth cells.
CONCLUSION
Considerable attention and progress has been made in under-
standing the cell sources and contribution of AMPs to defense
of the intestines. Multiple AMPs show regional patterns of expres-
sion in both axes of the intestines, longitudinally and within the
crypt-to-villus axis. The other antimicrobial system, complement,
is present and becomes activated in the mucosa but we are only
beginning to explore the impact of this activation, including on
AMP activity and expression. We offer some hypotheses for fur-
ther investigation into what is certain to be a closely coordinated
collaboration between the two systems in the defense of the host.
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